MYELOID NEOPLASIA Properties of CD34 CML stem/progenitor cells that correlate with different clinical responses to imatinib mesylate
نویسندگان
چکیده
1Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, BC; 2Department of Medical Genetics, University of British Columbia, Vancouver, BC; 3Department of Medicine, University of British Columbia, Vancouver, BC; 4Leukemia/BMT Program, British Columbia Cancer Agency, Vancouver, BC; 5Hematology Department, E. Herriot Hospital, Lyon, France; 6Inserm U935-University and Centre Hospitalier Universitaire Poitiers, Poitiers, France; 7Biostatistics Clinical Investigation Center, Inserm CIC 802 University, Poitiers, France; 8Department of Cell Biology, Harvard Medical School, Boston, MA; 9Section of Experimental Haematology, University of Glasgow, Glasgow, United Kingdom; and 10Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC
منابع مشابه
Properties of CD34+ CML stem/progenitor cells that correlate with different clinical responses to imatinib mesylate.
Imatinib mesylate (IM) induces clinical remissions in chronic-phase chronic myeloid leukemia (CML) patients but IM resistance remains a problem. We recently identified several features of CML CD34(+) stem/progenitor cells expected to confer resistance to BCR-ABL-targeted therapeutics. From a study of 25 initially chronic-phase patients, we now demonstrate that some, but not all, of these parame...
متن کاملMYELOID NEOPLASIA Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment
Imatinib mesylate treatment markedly reduces the burden of leukemia cells in chronic myelogenous leukemia (CML) patients. However, patients remain at risk for relapse on discontinuing treatment. We have previously shown that residual BCR-ABL progenitors can be detected in CML patients within the first 2 years of imatinib treatment. However, reduced rates of relapse and continued decline of BCR-...
متن کاملGrowth factor stimulation reduces residual quiescent chronic myelogenous leukemia progenitors remaining after imatinib treatment.
The BCR/ABL tyrosine kinase inhibitor imatinib mesylate is highly effective in the treatment of chronic myelogenous leukemia (CML) but fails to eliminate all leukemia cells. Residual leukemia stem and progenitor cells persist in imatinib-responsive patients and may be a potential source of relapse. Previous studies indicate that imatinib preferentially targets dividing cells, and nondividing pr...
متن کاملNEOPLASIA BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors
Chronic myeloid leukemia (CML), a hematopoietic stem-cell disorder, cannot be eradicated by conventional chemotherapy or the tyrosine kinase inhibitor imatinib mesylate (IM). To target CML stem/progenitor cells, we investigated BMS-214662, a cytotoxic farnesyltransferase inhibitor, previously reported to kill nonproliferating tumor cells. IM or dasatinib alone reversibly arrested proliferation ...
متن کاملBCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells.
Chronic myelogenous leukemia (CML) results from malignant transformation of a primitive hematopoietic cell by the BCR/ABL oncogene. The breakpoint cluster region/ABL (BCR/ABL) tyrosine kinase inhibitor imatinib mesylate (imatinib) is highly effective in inducing remissions in CML. However, the effects of imatinib on intracellular signaling in primary progenitor cells are not well described. We ...
متن کامل